Plasticity of afferent fibers to striatal neurons bearing D1 dopamine receptors in Parkinson's disease

Movement Disorders

Volumn 16, Issue 3, 2001, Pages 435-441

  Muriel, Marie Paule ^a   Agid, Yves ^a   Hirsch, Etienne ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Basal ganglia; Dopamine receptor; Parkinson; Plasticity

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; LEVODOPA;

AGED; ARTICLE; BASAL GANGLION; BRAIN MITOCHONDRION; CELL STRUCTURE; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC SPINE; DOPAMINERGIC NERVE CELL; DYSKINESIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOTOR DYSFUNCTION; NERVE CELL PLASTICITY; NERVE CELL STIMULATION; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSORY NERVE CELL; SUBSTANTIA NIGRA; SYNAPSE; ULTRASTRUCTURE;

AGED; AGED, 80 AND OVER; BASAL GANGLIA; BRAIN; CASE-CONTROL STUDIES; CAUDATE NUCLEUS; CORPUS STRIATUM; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, ELECTRON; MIDDLE AGED; NEURAL PATHWAYS; NEURONAL PLASTICITY; NEURONS, AFFERENT; PARKINSON DISEASE; RECEPTORS, DOPAMINE D1; SYNAPSES;

EID: 0035353763     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.1103     Document Type: Article

References (45)

1. Aizman O, Brismar H, Uhlén, P Zettergren E, Levey AI, Forssberg H, Greengard P, Aperia A. 2000. Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. Nat Neurosci 3:226-230.
2. Albin RL, Young AB, Penney. JB. 1989. The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366-375.
3. Anglade P, Blanchard V, Raisman-Vozari R, Faucheux BA, Herrero MT, Obeso JA, Mouatt-Prigent A, Kastner A, Strada O, Javoy-Agid F, Agid Y, Hirsch EC. 1996. Is dopaminergic cell death accompanied by concomitant nerve plasticity? Adv Neurol 69:195-208.
4. Anglade P, Mouatt-Prigent A, Agid Y, Hirsch E. 1996. Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration 5:121-128.
5. Berretta S, Parthasarathy HB, Graybiel AM. 1997. Local release of GABAergic inhibition in the motor cortex induces immediate-early gene expression in indirect pathway neurons of the striatum. J Neurosci 17:4752-4763.
6. Bolam JP, Smith Y. 1990. The GABA and substance P input to dopaminergic neurones in the substantia nigra of the rat. Brain Res 529:57-78.
7. Brana C, Aubert I, Charron G, Pellevoisin C, Bloch B. 1997. Ontogeny of the striatal neurons expressing the D2 dopamine receptor in humans: an in situ hybridization and receptor-binding study. Brain Res Mol Brain Res 48:389-400.
8. Brana C, Caille I, Pellevoisin C, Charron G, Aubert I, Caron MG, Carles D, Vital C, Bloch B. 1996. Ontogeny of the striatal neurons expressing the D1 dopamine receptor in humans. J Comp Neurol 370:23-34.
9. Caille I, Dumartin B, Bloch B. 1996. Ultrastructural localization of D1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation. Brain Res 730:17-31.
10. Caille I, Dumartin B, Le Moine C, Begueret J, Bloch B. 1995. Ontogeny of the D1 dopamine receptor in the rat striatonigral system: an immunohistochemical study. Eur J Neurosci 7:714-722.
11. Calabresi P, Mercuri NB, Sancesario G, Bernardi G. 1993. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 116:433-452.
12. Calverley RK, Jones DG. 1990. Contributions of dendritic spines and perforated synapses to synaptic plasticity. Brain Res Brain Res Rev 15:215-249.
13. Cash R, Raisman R, Ploska A, Agid Y. 1987. Dopamine D-1 receptor and cyclic AMP-dependent phosphorylation in Parkinson's disease. J Neurochem 49:1075-1083.
14. Cotman CW, Nieto-Sampedro M, Harris EW. 1981. Synapse replacement in the nervous system of adult vertebrates. Physiol Rev 61:684-784.
15. DeLong MR. 1990. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281-285.
16. Dumartin B, Caille I, Gonon F, Bloch B. 1998. Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists. J Neurosci 18:1650-1661.
17. Engber TM, Papa SM, Boldry RC, Chase TN. 1994. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 5:2586-2588.
18. Grondin R, Doan VD, Grégoire L, Bédard PJ. 1999. D1 receptor blockade improves L-dopa-induced dyskinesia but worsens p parkinsonism in MPTP monkeys. Neurology 52:771-776.
19. Hersch SM, Ciliax BJ, Gutekunst CA, Rees HD, Heilman CJ, Yung KK, Bolam JP, Ince E, Yi H, Levey AI. 1995. Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J Neurosci 15:5222-5237.
20. Hoehn MM, Yahr MD. 1967. Parkinsonism: onset, progression and mortality. Neurology 17:427-442.
21. Hornykiewicz O. 1975. Parkinson's disease and its chemotherapy. Biochem Pharmacol 24:1061-1065.
22. Ingham CA, Hood SH, Arbuthnott GW. 1991. A light and electron microscopical study of enkephalin-immunoreactive structures in the rat neostriatum after removal of the nigrostriatal dopaminergic pathway. Neuroscience 42:715-730.
23. Ingham CA, Hood SH, van Maldegem B, Weenink A, Arbuthnott GW. 1993. Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway. Exp Brain Res 93:17-27.
24. Kerns JM, Sierens DK, Kao LC, Klawans HL, Carvey PM. 1992. Synaptic plasticity in the rat striatum following chronic haloperidol treatment. Clin Neuropharmacol 15:488-500.
25. Langston JW, Koller WC. 1991. The next frontier in Parkinson's disease: presymptomatic detection. Neurology 41:5-7.
26. Levy R, Hazrati LN, Herrero MT, Vila M, Hassani OK, Mouroux M, Ruberg M, Asensi H, Agid Y, Féger J, Obeso JA, Parent A, Hirsch EC. Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states. Neuroscience 76:335-343.
27. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. 1994. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 9:2-12.
28. Marin C, Papa S, Engber TM, Bonastre M, Tolosa E, Chase TN. 1996. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res 736:202-205.
29. Marsden CD, Obeso JA. 1994. The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. Brain 117:877-897.
30. Meshul CK, Buckman JF, Allen C, Riggan JP, Feller DJ. 1996. Activation of corticostriatal pathway leads to similar morphological changes observed following haloperidol treatment. Synapse 22:350-361.
31. Meshul CK, Emre N, Nakamura CM, Allen C, Donohue MK, Buckman JF. 1999. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 88: 1-16.
32. Meshul CK, Stallbaumer RK, Taylor B, Janowsky A. 1994. Haloperidol-induced morphological changes in striatum are associated with glutamate synapses. Brain Res 648:181-195.
33. Monfort JC, Javoy-Agid F, Hauw JJ, Dubois B, Agid Y. 1985. Brain glutamate decarboxylase in Parkinson's disease with particular reference to a premortem severity index. Brain 108:301-313.
34. Muriel MP, Bernard V, Levey AI, Laribi O, Abrous DN, Agid Y, Bloch B, Hirsch EC. 1999. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease. Ann Neurol 46:103-111.
35. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN. 1995. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 701:13-18.
36. Papa SM, Chase TN. 1996. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 39:574-578.
37. Papa SM, Engber TM, Kask AM, Chase TN. 1994. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662:69-74.
38. Parent A, Cicchetti F. The current model of basal ganglia organization under scrutiny. Mov Disord 13:199-202.
39. Pimoule C, Schoemaker H, Reynolds GP, Langer SZ. 1985. [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur J Pharmacol 114:235-237.
40. Reiner A, Medina L, Haber SN. 1999. The distribution of dynorphinergic terminals in striatal target regions in comparison to the distribution of substance P-containing and enkephalinergic terminals in monkeys and humans. Neuroscience 88:775-793.
41. Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW. 1987. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1:5-15.
42. Smith AD, Bolam JP. 1990. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci 13:259-265.
43. Uhl GR, Navia B, Douglas J. 1988. Differential expression of preproenkephalin and preprodynorphin mRNAs in striatal neurons: high levels of preproenkephalin expression depend on cerebral cortical afferents. J Neurosci 8:4755-4764.
44. Zhou FC, Bledsoe S, Murphy J. 1991. Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res 556:108-116.
45. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. 1990. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13:290-296.